stockportfolio.pro
Avalo Therapeutics, Inc. (AVTX)
Healthcare · Biotechnology · NasdaqCM
Avalo Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.15M | $27.81M | $7.03M | $6.75M | $6.70M | $5.40M | $18.05M | $1.92M | $441,000 | $59,000 |
| Gross profit | — | $27.18M | $3.77M | $7.32M | $6.40M | $3.91M | $14.62M | $640,000 | $807,000 | $59,000 |
| Net income | $-16.47M | $11.87M | $-40.05M | $-16.07M | $-63.50M | $-84.38M | $-41.66M | $-31.54M | $-35.13M | $-78.26M |
| Net margin | -1428.6% | 42.7% | -569.9% | -238.1% | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
Source: Avalo Therapeutics, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of Avalo Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AVTX in your portfolio →
Avalo Therapeutics, Inc. financial history by metric
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Avalo Therapeutics, Inc. — frequently asked questions
What is Avalo Therapeutics, Inc.'s revenue?
Avalo Therapeutics, Inc. (AVTX) reported revenue of $59,000 for fiscal year 2025, down 86.6% from the prior year, according to its SEC filings.
Is Avalo Therapeutics, Inc. profitable?
No — AVTX reported a net loss of $-78.26M in fiscal 2025.
What is AVTX's P/E ratio?
Avalo Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Avalo Therapeutics, Inc. growing?
AVTX's revenue grew at roughly -61.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Avalo Therapeutics, Inc. have?
As of fiscal year 2025, AVTX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Avalo Therapeutics, Inc.'s gross margin?
AVTX's gross margin was 100.0% in fiscal 2025 — gross profit of $59,000 on revenue of $59,000.
What is Avalo Therapeutics, Inc.'s market cap?
Avalo Therapeutics, Inc. (AVTX) has a market capitalization of about $721.73M, based on the latest data in our nightly-refreshed cache.
When does Avalo Therapeutics, Inc.'s fiscal year end?
AVTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Avalo Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.